Clinical trials: Seizures
Nonconvulsive Status Epilepticus, Subclinical Seizure
EEG Cap for Identification of Non-Convulsive Status Epilepticus
Altered mental status (AMS) is one of the most common reasons for inpatient neurology consultation. Non-convulsive status epilepticus (NCSE) is frequently on the differential diagnosis of the patient with AMS.
- Conditions
- Nonconvulsive Status Epilepticus, Subclinical Seizure, Altered Mental Status, Nonepileptic Seizures
- Trial name
- NCT03138876
- Testing
- EEG Cap, Anti-seizure medication, Standard EEG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
PCDH19-Related Epilepsy
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)
A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in female children and young adults with genetically confirmed PCDH19 gene…
- Trial name
- NCT03865732
- Testing
- Ganaxolone
- Where
- 12 sites in United States, Hungary and 3 more
- Volunteers
- 29 people
- Sponsor
- Marinus Pharmaceuticals
Partial Epilepsy
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
To evaluate the effects of eslicarbazepine acetate on cognition in comparison with placebo as adjunctive therapy in children aged 6 to 16 years old with refractory partial-onset seizures.
- Trial name
- NCT01527513
- Testing
- Eslicarbazepine acetate (BIA 2-093)
- Where
- 36 sites in Italy, Netherlands and 3 more
- Volunteers
- 123 people
- Sponsor
- Bial - Portela C S.A.
Partial Epilepsies, Partial Onset Seizures
Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
The purpose of the trial is to evaluate the safety of intravenous (iv) lacosamide delivered in a single dose followed by 6.5 days of oral lacosamide treatment in subjects with partial-onset seizures.
- Trial name
- NCT00655551
- Testing
- lacosamide
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
Study to evaluate the efficacy of Lacosamide (LCM) administered in addition to 1 to ≤3 other Anti-Epileptic Drugs in subjects with epilepsy ≥4 years to <17 years of age who currently have uncontrolled partial onset seizures.
- Trial name
- NCT01921205
- Testing
- Lacosamide
- Where
- 118 sites in United States, Argentina and 26 more
- Volunteers
- 404 people
- Sponsor
- UCB Pharma
Epilepsy
Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures
Zonisamide is already marketed for the treatment of partial seizures in epilepsy. This study is intended to provide evidence that zonisamide is safe and effective in the treatment of primary generalised tonic-clonic seizures.
- Trial name
- NCT00692003
- Testing
- Zonisamide
- Where
- 73 sites in Australia, Croatia and 11 more
- Volunteers
- 21 people
- Sponsor
- Eisai Limited